Novo Nordisk’s Amycretin Shows Promise, FDA Expands Gene Therapy Access
A new diabetes and weight loss drug from Novo Nordisk is delivering positive results in clinical trials, while the FDA has broadened access to a costly gene therapy for spinal muscular atrophy.
The pharmaceutical landscape saw significant developments this week, with a potential new treatment emerging from Novo Nordisk and expanded access granted to a life-altering, yet expensive, therapy from Novartis. While the U.S. prepares for the Thanksgiving holiday, the pharmaceutical industry continues to move at a rapid pace, particularly in Europe, where preparations for the Christmas season are already underway.
Novo Nordisk’s Amycretin Advances in Phase 2 Trials
Novo Nordisk is reporting encouraging data from a Phase 2 trial of amycretin, a next-generation treatment for diabetes. According to a report from Bloomberg, the drug demonstrated success in helping patients lower blood sugar levels and achieve weight loss. This news represents a crucial win for Novo Nordisk, which has faced increasing competition from Eli Lilly as its existing diabetes and obesity medications lose market share.
Amycretin is currently being tested in both injectable and oral formulations. The company is also evaluating its efficacy in treating obesity. A senior official stated that Novo Nordisk plans to initiate a Phase 3 study of amycretin for diabetes treatment next year. This advancement signals a potential new weapon in the fight against diabetes and obesity, two increasingly prevalent global health concerns.
FDA Expands Access to Novartis’ Itvisma Gene Therapy
The U.S. Food and Drug Administration has approved an expanded indication for Itvisma, a gene therapy manufactured by Novartis, to include older patients suffering from a rare muscle disorder. Reuters reports that the therapy is now authorized for the treatment of spinal muscular atrophy (SMA) in patients aged 2 years and older who have a confirmed mutation in the survival motor neuron 1 gene.
Itvisma utilizes the same active ingredient as Zolgensma, Novartis’ existing gene therapy for SMA, which is currently approved for patients under the age of 2. However, the expanded approval significantly broadens the potential patient population. The wholesale acquisition cost for Itvisma is $2.59 million, a slight increase from Zolgensma’s price of $2.1 million. This high cost underscores the ongoing debate surrounding the affordability and accessibility of gene therapies, even as they offer potentially life-changing benefits.
These developments highlight the continued innovation within the pharmaceutical industry, bringing new hope to patients while simultaneously raising complex questions about access and cost.
